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Background and Objectives. The majority of cancer
patients suffer from chronic anemia. While recombinant
human erythropoietin (rHuEPO) offers many of the advan-
tages of blood transfusions, response rates to this treat-
ment are variable and in some trials a large proportion of
patients (30–50%) did not respond. This failure may be
due to factors related to the underlying disease, the
chemotherapy given or functional iron deficiency. An accu-
rate means of predicting response to rHuEPO would be
beneficial to both healthcare providers and patients.
Evidence and information sources. Data were identified by
searches of the published literature, including PubMed,
references from relevant reviews, and abstracts presented
at recent international oncology and hematology meet-
ings. Only papers in English published between 1990 and
2002 were included. References were selected according
to direct relevance to the topic discussed and availability. 
State of the art. The best algorithms for predicting
response appear to be those combining an assessment
of the adequacy of endogenous erythropoietin production
together with some early indicators of erythropoietic mar-
row response. Further characterization of the dose-
response relationship of erythropoietic agents may allow
better understanding of ways in which response may be
enhanced. Adequate iron availability could also contribute
to better response rates.
Perspectives. Further characterization of the predictors
of response for current and upcoming erythropoietic
agents may enhance the management of anemia associ-
ated with cancer, and provide more convenient, effective,
and flexible therapy.
©2002, Ferrata Storti Foundation
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Chronic anemia is a common complication ofcancer and its treatment, and occurs in overhalf of all cancer patients at diagnosis or
during the course of the disease.1 While the inci-
dence of severe anemia in patients with cancer is
relatively high in all tumor types, rates are higher
among patients with lymphomas, lung tumors or
gynecologic tumors (50–60%)2 for example, than
among those with colorectal or breast cancer (10-
20%).3
The etiology of the anemia of cancer is multi-
factorial, and still not fully understood. Anemia
may occur as a consequence of the chronic disease
process associated with malignancy, and is there-
fore often termed anemia of chronic disease (ACD).
A shortened red blood cell (RBC) lifespan and fail-
ure of the bone marrow to increase RBC produc-
tion to compensate are believed to be key con-
tributors to the pathogenesis of ACD.4 Increased
production of inflammatory cytokines has been
implicated in suppressing erythropoietic progeni-
tors, blocking storage iron in macrophages and
inhibiting the production of erythropoietin (EPO),
the primary hematopoietic growth factor.5 Anemia
may also arise as a result of RBC loss (from hemo-
lysis or bleeding), a reduction in RBC production
caused by the cancer (for example, because of
bone marrow infiltration, hemophagocytosis or
nutritional deficiencies),6 or as a side effect of
chemo- or radiotherapy.7
The clinical manifestations of anemia, which
commonly include fatigue, exertional dyspnea,
depression, anorexia, indigestion and a reduced skin
temperature,3 have traditionally been overlooked or
regarded as an inevitable consequence of cancer.
However, there is growing recognition that chron-
ic anemia has a significant negative impact on the
already impaired quality of life (QOL) of cancer
patients. Furthermore, evidence suggests that ane-
mia may be an independent predictor of a poor clin-
ical outcome in cancer patients; it is not known
whether this is merely an indicator of more
advanced disease or an adverse prognostic factor
because it increases tumor resistance to anticancer
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therapy.8 However, the chronic anemia that is so fre-
quently associated with cancer may be not only
treatable, but also, to some extent, preventable with
erythropoiesis-stimulating proteins.9–11
Current therapy for anemia includes RBC trans-
fusions and recombinant human erythropoietin
(rHuEPO). rHuEPO is invaluable in raising hemo-
globin (Hb) levels and improving QOL. However, this
therapy has a number of limitations, which will be
discussed in this paper. One of the limitations of
rHuEPO — the failure of a substantial proportion of
patients to respond to standard doses — will be
explored in detail together with the value of iden-
tifying predictive factors for response to rHuEPO.
Further approaches to enhance the current man-
agement of anemia, such as iron supplementation
and modified schedules of administration (includ-
ing those allowed by the new erythropoietic pro-
tein, darbepoetin α) are also discussed. 
Factors influencing the risk of
cancer-associated anemia and
transfusions
Clearly, it would be of great benefit to be able to
predict which patients are most likely to develop
anemia, particularly those undergoing chemother-
apy or radiotherapy, as the incidence of anemia is
high among this group.2,12 The likelihood of a
patient who is receiving chemotherapy developing
anemia depends on several factors, including the
type, schedule and intensity of therapy.2 For exam-
ple, platinum-based chemotherapy, which forms
the basis of first-line therapy for lung and ovarian
cancer, is particularly myelotoxic, and produces
severe anemia in up to 23% of patients with lung
cancer, and in up to 42% of patients with ovarian
cancer.2 In contrast, newer agents such as the tax-
anes (paclitaxel and docetaxel), vinorelbine and
gemcitabine are associated with higher incidences
of mild-to-moderate anemia and lower incidences
of severe anemia in patients with lung cancer.
Several researchers have identified factors that
may predispose patients to developing anemia, pri-
marily severe anemia requiring transfusion, which
are listed in Table 1.13–20 Ray-Cocquard et al.17 have
developed the only predictive algorithm to date, a
risk model that estimates the likelihood of devel-
oping severe anemia requiring transfusion within
31 days of starting chemotherapy. This algorithm
requires the calculation of a Risk Index Score
according to the presence of three factors: perfor-
mance status >1; day-1 (of chemotherapy) lym-
phocyte count ≤700/µL; and day-1 Hb level of <12
g/dL.17 The presence of each of the first two factors
receives a score of 1 each, while a low baseline Hb
level receives a score of 3. The individual scores are
added (giving a maximum of 5), and the probabil-
ity of developing severe anemia requiring transfu-
sion within 31 days after the start of chemothera-
py for each total score is determined using the val-
ues given in Table 2.
While several investigations have identified pos-
sible predictive factors, many studies have been
limited by their retrospective nature, which has
restricted analysis to only those measurements that
were taken as part of routine care. Consequently,
few studies examine the same potential predictive
factors, making it difficult to draw conclusions. In
addition, while some investigators found evidence
of an association between particular risk factors
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Table 1. Factors that may be predictive of the development





- etoposide or 5-fluorouracil15
- carboplatin- versus cisplatin-containing18
- higher ultrafilterable platinum concentration19
Low baseline Hb level13,14,16,18–20
Performance status >117
Lymphocyte count ≤700/mL on day 1 of chemotherapy17







History of prior transfusions16
Longer duration of chemotherapy16
Metastatic disease13
Hb: hemoglobin.
Table 2. Probability of developing severe anemia requiring
RBC transfusion within 31 days after starting chemothera-
py, according to the Risk Index Score (see text for calcu-
lation of Risk Index Score).17
Calculated probability of receiving RBC transfusion
Risk Index Score % 95% CI
≥4 30 16–47
2 or 3 11.4 7–18
1 3.8 3–5
0 1.2 1–2
RBC: red blood cell; Ci: confidence interval.
and anemia, others specifically noted no associa-
tion for these factors.
However, although no factor besides low baseline
Hb levels has consistently been associated with an
increased risk of developing anemia during the
course of treatment, physicians would be well
advised to consider whether each individual patient
possesses any number of the risk factors identified.
Certainly, low baseline Hb appears to be a strong
indicator of the likelihood of anemia worsening
during therapy, and certain tumor types (for exam-
ple, hematologic, lung or ovarian) and chemother-
apy regimens (for example, cisplatin-containing)
are more likely than others to be associated with
the development of anemia.
Management of cancer-associated
anemia
At present, two principal options are available for
the management of chronic anemia in patients with
cancer: blood transfusions and treatment with
rHuEPO. Blood transfusions have traditionally been
given when severe anemia (Hb <8 g/dL) develops,21
and rapid relief of anemia is required. The decision
to treat with rHuEPO is usually determined by
patients’ Hb levels and symptoms; rHuEPO has gen-
erally been given to patients when their Hb levels
have dropped to <10 g/dL. With increasing recog-
nition that treatment of even mild-to-moderate
anemia (Hb levels approximately 8-12 g/dL) can
lead to a significant improvement in QOL,22 rHuEPO
therapy is now being considered for higher Hb lev-
els, as dictated by symptoms.
Blood transfusions
Despite significant advances in this area, con-
ventional red blood cell transfusions are still asso-
ciated with a number of serious risks that must be
taken into account in any treatment decision,
although the odds of developing these complica-
tions are minimal. These include risks of transmis-
sion of viral or bacterial infections;23 pulmonary
edema; hemolytic reactions; allergic reactions to
donor proteins; progressive iron overload; and
alloimmunization to RBC and platelet antigens.23,24
The inconvenience to patients, and the time and
financial costs incurred by hospitals and clinics, are
further disincentives for the use of blood transfu-
sions in the routine management of cancer-asso-
ciated anemia.3 It must be noted, however, that in
chronically and terminally ill patients, the hazards
associated with transfusions may be of little or no
consequence given that the patients’ lifespan may
already be substantially reduced.
Treatment with rHuEPO
The ability of rHuEPO to correct cancer-associ-
ated anemia was first demonstrated in patients
with low-grade lymphoma or multiple myeloma,
all of whom were anemic as a consequence of the
underlying disease.25 Further studies have con-
firmed and expanded these early findings, demon-
strating that treatment with rHuEPO raises Hb lev-
els, reduces the need for RBC transfusions, and
improves QOL.22,26-35 rHuEPO is also effective when
administered prophylactically to prevent or post-
pone the onset of chemotherapy- or radiotherapy-
induced anemia.9,10,36
Limitations of rHuEPO treatment
Clinical trials have demonstrated that rHuEPO
provides many of the benefits of blood transfusions
- albeit significantly more slowly - without the risks
associated with the transfusion of allogeneic blood.
Nevertheless, despite the proven safety and effi-
cacy of rHuEPO in correcting cancer-related ane-
mia in a significant proportion of patients, thera-
peutic response rates vary markedly among
patients receiving treatment, and in some trials, as
many as 40–50% of patients with cancer-associ-
ated anemia failed to derive any clinical benefit
from rHuEPO.22,26,29,30 The median time to response
(Hb increment >2 g/dL) is approximately 6 to 10
weeks in patients with myeloid or lymphoprolifer-
ative malignancies,34,35,37–39 approximately 7 weeks
in patients with nonmyeloid malignancies,22 and
occasionally up to 12 weeks are needed to rule out
unresponsiveness in an individual patient.40
Factors contributing to failure of rHuEPO
treatment
Despite the fairly high proportion of patients who
do not respond to rHuEPO, relatively little is known
about the causes of this treatment failure. Several
disease- and treatment-related factors have been
identified that may reduce a patient’s response to
rHuEPO treatment (Table 3). Although most of
these were identified in patients with chronic kid-
ney disease, they are also likely to apply to patients
with cancer.
Of these factors, functional iron deficiency is
likely to be one of the most significant and com-
mon contributing factors. This is defined as an iron
deficit in the functional erythroid compartment,
and is the result of an imbalance between iron
needs in the erythroid marrow and iron supply. This
may occur even in the presence of large iron stores
(increased ferritin) when the release of stored iron
is inadequate.6 Although the vast majority of
patients with chronic kidney disease treated with
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rHuEPO develop functional iron deficiency that
seriously limits their erythropoietic response,41 this
has not been specifically examined in cancer
patients. However, there is every reason to believe
that its prevalence is also very high in this setting.
Functional iron deficiency is best diagnosed by a
transferrin saturation level below 20% or a fraction
of hypochromic red cells greater than 10%.
Inflammation (and its accompanying pro-inflam-
matory cytokines), infections, hemorrhage and
complications of chemotherapy may also have a
profound negative impact on response to rHuEPO
treatment.42 Surgery is often followed by a tran-
sient loss of response to rHuEPO, not only because
of blood loss, but also because iron reutilization is
impaired post-operatively.43 Blood loss and hemol-
ysis, while not directly reducing the erythropoiet-
ic effect of rHuEPO, may be manifested as an
apparently poor response to rHuEPO because of
increased RBC losses.44
Although vitamin B12 and folate deficiencies are
less common than deficiency of iron, they may con-
tribute to a poor response to rHuEPO, as both are
essential for RBC development.44 Vitamin B12 and/or
folate deficiencies are likely to be more common in
patients with gastrointestinal malignancies, in
which malabsorption secondary to surgical resec-
tion may occur.
Bone marrow metastases may impair response
to rHuEPO in cases in which there is major invasion
by cancer cells and limited residual normal
hematopoiesis, however, bone marrow involvement
does not otherwise appear to affect the efficacy of
treatment with rHuEPO.25,32 In addition, conditions
causing inherent disorders of erythropoiesis (for
example, myelodysplastic syndrome, aplastic ane-
mia or some of the hemoglobinopathies) may
reduce the effectiveness of rHuEPO, with some
patients showing a profound resistance to rHuEPO,
even at high doses.44
In addition, chemotherapy may affect the body’s
ability to respond to rHuEPO. More intensive
chemotherapy regimens are associated with lower
rates of response to rHuEPO, the extreme example
being autologous bone marrow transplantation in
which rHuEPO therapy is not efficient in the early
post-transplant period.45 However, patients receiv-
ing chemotherapy of moderate intensity respond
as well to rHuEPO as those not receiving concomi-
tant chemotherapy,32 and there is no marked dif-
ference between those receiving platinum-based
regimens and those receiving other forms of
chemotherapy.31,32
The type of tumor does not generally appear to
affect response rate,32 although small studies have
suggested that patients with breast or colon can-
cer may derive less benefit from rHuEPO than those
with myeloma.46 A meta-analysis has produced
similar findings, reporting higher response rates in
patients with multiple myeloma compared with
other types of cancer.47 However, these differences
may also reflect variations in the myelosuppressive
effects of the various forms of chemotherapy.
Improvements in erythropoietic therapy
Predicting response to rHuEPO
Considering the wide variation in the response of
cancer patients to rHuEPO, the development of an
algorithm to facilitate accurate identification of
those patients who are more likely to demonstrate
an adequate treatment response would be
extremely valuable. Ideally, this would enable the
targeting of therapy to those patients who would
benefit significantly from this treatment approach,
thus minimizing the risk of prolonged treatment
without clinical benefits.
A predictive algorithm of response to rHuEPO
was first proposed in the setting of the anemia
associated with renal failure.48 Sixty-four consec-
utive unselected hemodialysis patients received
intravenous rHuEPO three times weekly, at a start-
ing dose of 50 U/kg, which was increased to 75
and 100 U/kg if no response was observed after 1
and 2 months of treatment, respectively. The val-
ue of various laboratory parameters (including
baseline values and early changes) as predictors of
response to rHuEPO were analyzed retrospectively.
Using various statistical methods, the investigators
found that baseline fibrinogen (an indicator of
inflammation) and serum soluble transferrin recep-
tor (sTfR; a marker of functional iron deficiency), as
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Table 3. Factors limiting the efficacy of rHuEPO therapy.
Factor






Folate or vitamin B12 deficiency
Massive marrow infiltration




well as the early sTfR increment (a quantitative
measure of erythropoietic activity), were the most
useful predictors of response to rHuEPO. When only
pretreatment parameters were used in the predic-
tive model, a 100% response rate was observed
when sTfR and fibrinogen were both low, whereas
when both variables were high the response rate
was 29% (Table 4). In the second predictive mod-
el used, the increment in sTfR over the first 2 weeks
of treatment was also included. When the 2-week
sTfR increment was over 20%, or when both base-
line sTfR and fibrinogen were low, response rates of
greater than 95% were observed. In contrast, vir-
tually no response was observed when the sTfR
increment was low and baseline fibrinogen was
elevated (Table 4). These predictive factors illus-
trate the importance of the early erythropoietic
response (changes in sTfR levels), subclinical
inflammation (fibrinogen) and functional iron defi-
ciency (baseline sTfR).
Ludwig et al.37 conducted an in-depth investiga-
tion of the prognostic significance of 21 different
hematologic and humoral variables in patients with
chronic anemia of cancer. Eighty patients, six of
whom received chemotherapy and one of whom
was irradiated during the first 2 weeks of rHuEPO
treatment, were given rHuEPO at an initial dose of
150 U/kg three times weekly. Patients not respond-
ing with an increase in Hb of ≥2 g/dL after 6 weeks
of treatment had their rHuEPO dose increased to
300 U/kg. Of the 80 patients, 37 had hematologic
malignancies and 43 had solid tumors. Multivari-
ate discriminant analysis and logistic regression
analyses of response were performed on the results
of routine blood tests from the 76 patients who
received rHuEPO for at least 2 weeks in an attempt
to identify potential response predictors. None of
the baseline variables, which included concentra-
tions of Hb, reticulocytes, sTfR, EPO, ferritin, trans-
ferrin, platelets and several cytokines and acute-
phase proteins, were sufficiently strongly associat-
ed with response to rHuEPO treatment to serve as
a reliable prognostic indicator. On the other hand,
data collected after 2 weeks of treatment proved
more useful. The algorithm developed from this
study is shown in Figure 1, and offers two options.
Firstly, if after 2 weeks of therapy, serum erythro-
poietin is >100 mU/mL and Hb concentration has
increased by <0.5 g/dL, it is very likely the patient
will not respond to rHuEPO (predictive power
93%).37 Of the patients who do not fulfill these cri-
teria, response can be predicted with an accuracy
of 80%. Among such patients, if the serum ery-
thropoietin level is <100 mU/mL and the Hb con-
centration has increased by >0.5 g/dL, the proba-
bility of response to rHuEPO is very high (accuracy
95%). For the others (30 of the 76 patients), the
mean response rate was approximately 70%. If the
first option cannot be used (for example, the
required laboratory measurements cannot be
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Table 4. Prediction of response to rHuEPO in hemodialysis
patients using baseline levels of sTfR and fibrinogen, with
or without 2-week sTfR increment.48
2-week sTfr Baseline level Baseline level Response 
increment (%) of sTfr (ng/mL) of fibrinogen (g/L) rate (%)
Model 1: using baseline parameters only
− <3,500 <4 100
− ≥3,500 <4 67
− <3,500 ≥4 67
− ≥3,500 ≥4 29
Model 2: including 2-week sTfR increment
≥20 − − 96
<20 <3,500 <4 100
<20 <3,500 ≥4 12
<20 ≥3,500 <4 62
Figure 1. Prediction of response to rHuEPO in anemia of
cancer patients using the 2-week absolute serum EPO lev-
el and the Hb increment.37 (Ludwig H, personal communi-
cation 2001). (A) 2-week serum EPO <100 mU/mL and Hb
increment >0.5 g/dL, n = 15; (B) 2-week serum EPO <100
mU/mL and Hb increment <0.5 g/dL, n = 13; (C) 2-week
serum EPO >100 mU/mL and Hb increment >0.5 g/dL,
n = 17; (D) 2-week serum EPO >100 mU/mL and Hb incre-
ment <0.5 g/dL, n = 31.
obtained), a serum ferritin level of ≥400 ng/mL
after 2 weeks of rHuEPO therapy strongly indicates
unresponsiveness (predictive power 88%). In con-
trast, a serum ferritin level of <400 ng/mL suggests
response in three out of four patients.
In a subset of patients with hematologic malig-
nancies or solid tumors from a large multicenter
study, some prediction of response could be derived
from changes observed in reticulocytes and Hb from
baseline to week 2 of therapy.49 Patients receiving
chemotherapy (n = 132) were given rHuEPO at 150
U/kg or placebo subcutaneously three times week-
ly for 12 weeks, while another set of patients not
receiving chemotherapy (n=54) was given rHuEPO
at 100 U/kg or placebo subcutaneously three times
weekly for up to 8 weeks. Overall, 54% of patients
receiving chemotherapy responded to rHuEPO with
an increase in Hb of ≥ 2 g/dL, while only 32% of
patients not receiving chemotherapy responded.
Patients were retrospectively stratified by changes
in Hb and absolute reticulocyte count at weeks 2
and 4. Among patients not receiving chemotherapy
(Figure 2A), the response rate was poor when the 2-
week increment of the Hb level was <0.5 g/dL (7%),
but it was greatly improved when the Hb level and
reticulocyte count increased by ≥ 0.5 g/dL and
≥ 40,000/µL, respectively (91%).49 The predictive
power of these parameters was much less substan-
tial when Hb increased by ≥0.5 g/dL and the retic-
ulocyte elevation was <40,000/µL (a 36% response
rate). In contrast, adequate prediction of response
could not be provided on the basis of Hb and retic-
ulocyte changes in patients receiving concomitant
chemotherapy (Figure 2B).49 Although some
improvement in prediction could be obtained in
patients increasing their Hb by ≥ 1 g/dL after 4
weeks of treatment, predicting response on the basis
of the response itself may appear to be trivial.
Theoretically, patients with defective endogenous
EPO production would be more likely to respond to
rHuEPO than those with adequate serum EPO lev-
els. In a study by Osterborg et al.,35 patients with
anemia associated with multiple myeloma or low-
grade non-Hodgkin’s lymphoma (NHL) (of whom
88% received chemotherapy throughout the study)
were randomized to receive subcutaneous rHuEPO
at a fixed dosage (10,000 U/day) or at a titrated
dosage (2,000 U/day for 8 weeks, then increased in
a stepwise manner to 10,000 U/day). The presence
of a deficiency of EPO relative to the degree of ane-
mia (a relative EPO deficiency) was analyzed in
each patient prior to the initiation of therapy by
calculating the ratio between observed (O) and pre-
dicted (P) baseline serum EPO concentrations: the
O/P EPO ratio. rHuEPO appeared most effective in
those patients with a deficiency in EPO relative to
the degree of anemia (O/P EPO ratio < 0.9), and
patients with an O/P EPO ratio of < 0.6 had a very
high response rate (89%). Unresponsiveness to
rHuEPO could be predicted with a high probabili-
ty, as the response rate among patients with an
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Figure 2. Prediction of response to rHuEPO in anemia of
cancer patients using the 2-week Hb and reticulocyte incre-
ments.49 A good prediction can be obtained in patients not
receiving chemotherapy, n = 54 (Figure 2A), but not in
those receiving chemotherapy, n = 132 (Figure 2B). (A) 2-
week Hb increment ≥0.5 g/dL and reticulocyte increment
≥40,000/µL; (B) 2-week Hb increment ≥0.5 g/dL and retic-
ulocyte increment <40,000/µL; (C) 2-week Hb increment
<0.5 g/dL and reticulocyte increment ≥40,000/µL; (D) 2-
week Hb increment <0.5 g/dL and reticulocyte increment
<40,000/µL.
O/P EPO ratio ≥1.2 was only 10%. As it was felt
that in clinical practice it would be more useful to
relate the (uncorrected) serum EPO concentrations
to the probability of response, the investigators
also assessed the predictive value of observed EPO
concentrations. Using cut-off values of 50 mU/mL
and 400 mU/mL, a baseline serum EPO concentra-
tion of <50 mU/mL was found to be associated
with a response rate of >76%, whereas a value
≥400 mU/mL strongly predicted non-response
(cumulative response rate 9%). Multivariate analy-
sis confirmed that relative EPO deficiency (low O/P
EPO ratio) was the most important factor in deter-
mining response to rHuEPO. A decreased platelet
count (<100×109/L) was also associated with a
lower probability of response.
In patients with hematologic malignancies, low
baseline serum EPO levels or a decreased O/P EPO
ratio were associated with a significantly higher
probability of response.34,35,37–39 In contrast, studies
in patients with solid tumors have failed to confirm
this observation. However, this may be the result of
inadequate timing of serum EPO sampling; indeed,
serum EPO should be evaluated just prior to
chemotherapy because decreased EPO utilization by
target cells causes inappropriately elevated serum
EPO levels in the 2 weeks after chemotherapy.50
A combination of baseline parameters and early
changes observed after 2 weeks of rHuEPO thera-
py may provide another useful approach.34 Patients
with multiple myeloma or non-Hodgkin’s lym-
phoma, of whom 79% received chemotherapy dur-
ing the study, were randomized to receive 8 weeks
of therapy with subcutaneous rHuEPO at doses
ranging from 1000 to 10,000 U/day. Seventy-sev-
en percent of patients had an inadequate produc-
tion of endogenous EPO, as judged by an O/P EPO
ratio of ≤0.9. The authors performed regression
analysis, using a Cox’s proportional hazard model,
and classification and regression tree analysis to
identify the most important factors predicting
response in patients receiving 5000 and 10,000 U
of rHuEPO daily. The failure rate was high when
the baseline serum O/P EPO ratio was higher than
0.9 (87%), or when the baseline serum O/P EPO
ratio was less than 0.9 and the 2-week Hb incre-
ment was <0.3 g/dL (100%) (Figure 3).34 On the
other hand, the success rate was 88% when the
baseline serum O/P EPO ratio was less than 0.9 and
Hb increased by ≥ 0.3 g/dL. A baseline serum EPO
concentration of ≤ 50 mU/mL in combination with
the 2-week change in Hb of ≥0.3 g/dL was also
found to predict success with an accuracy of
around 90%.
The potential value of the combination of baseline
parameters and changes in indicators of erythro-
poietic activity was demonstrated in another single-
center study.39 Fifty-eight anemic patients with
hematologic malignancies (n = 38) and solid tumors
(n = 20) received a starting dose of 375 U/kg/week
rHuEPO, administered subcutaneously once daily, for
5 days per week. Patients who did not respond
(response was defined as an increase in Hb of
≥2 g/dL in the absence of a red blood cell transfu-
sion) after 4 weeks of therapy had their dose
increased to 750 U/kg/week for another 4 weeks.
The value of a variety of laboratory parameters
(baseline levels, 2-week and 4-week changes) was
studied using multiple regression analysis. An
inverse relationship between the 8-week (end of
study) change in Hb and the baseline serum O/P EPO
ratio (p<0.001) was noted; however, absolute base-
line serum EPO and sTfR increments after 2 weeks
were found to be the most useful variables when
developing a predictive algorithm. Only 18% of
patients with a baseline serum EPO >100 mU/mL
responded to treatment, and only 29% of patients
responded when the baseline serum EPO was <100
mU/mL but the 2-week sTfR increment was <25%
(Figure 4). On the other hand, the response rate was
96% among patients with a low baseline serum EPO
and sTfR elevation of ≥25%.
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Figure 3. Prediction of response to rHuEPO in anemic
patients with NHL or multiple myeloma using the baseline
serum O/P EPO ratio and the 2-week Hb increment.34 (A)
Baseline O/P serum EPO >0.9, n = 8; (B) Baseline O/P
serum EPO <0.9 and Hb increment <0.3 g/dL, n = 6; (C)
Baseline O/P EPO <0.9 and Hb increment ≥0.3 g/dL, n =
34.
Thus, retrospective studies have shown that it
may be possible to predict, soon after initiating
therapy with rHuEPO, which patients with cancer-
associated anemia are likely to benefit from this
particular treatment approach. Several algorithms
have been proposed; their sensitivity (how well the
algorithm identifies all those who will respond) and
specificity (how well the algorithm excludes all
those who will fail), and thus their overall effica-
cy, vary. The positive predictive value (probability of
response in those predicted to respond) of the algo-
rithms is usually better than their negative predic-
tive value (probability of failure in those predicted
to fail). The best algorithms appear to be those
combining an assessment of the adequacy of
endogenous EPO production together with some
early indicators of erythropoietic marrow response,
such as the 2-week increment of sTfR or Hb.
There are some theoretical reasons why some or
all of these parameters might not be of value in
certain situations. Whereas low baseline serum EPO
levels or inadequate O/P ratios were associated
with a significantly higher probability of response
in patients with hematologic malignancies, this
was not usually the case in patients with solid
tumors. On the other hand, Hb increments after 2
weeks of treatment may be of value in patients
whose Hb levels are in a steady state, but are of lit-
tle help in transfused patients and in those in
whom rHuEPO is intended to prevent the occur-
rence of severe anemia.51 Changes in reticulocyte
counts may simply reflect the output of shift retic-
ulocytes and not a true expansion of erythropoiesis,
and often have not been found to be a good indi-
cator of response. Finally, although sTfR levels rep-
resent the best quantitative measurement of total
erythropoietic activity, they may also increase
slightly, secondary to functional iron deficiency.
It should be emphasized that the various algo-
rithms described here address very similar predic-
tors of response. Specifically, they all examine the
appropriateness of baseline endogenous EPO pro-
duction and/or early indicators of erythropoietic
marrow response to rHuEPO. In practise, the fol-
lowing scheme could be adopted: serum EPO
should be measured at baseline in patients with
hematologic malignancies and treatment with
rHuEPO not initiated if endogenous serum EPO is
>100 mU/mL (or >200 mU/mL in severely anemic
patients) or the O/P ratio is >0.9. Erythropoietic
response should be assessed after 2 weeks. In non-
transfused patients, if Hb has increased by at least
0.3 g/dL, rHuEPO treatment should be continued. If
the Hb level has not increased, the rHuEPO dosage
should be doubled and Hb measured again after a
further 2 weeks of treatment; if Hb has not
increased by >0.3 g/dL after the additional 2 weeks,
rHuEPO should be discontinued. In transfused
patients, if sTfR has increased by at least 20%,
rHuEPO treatment should be continued. If not, the
rHuEPO dosage should be doubled and sTfR mea-
sured again 2 weeks later. If sTfR has not increased
by at least 20% after the additional 2 weeks, rHuE-
PO should be discontinued. It is, of course, critical
that all preventable causes of rHuEPO failure are
identified prospectively and corrected, or else no
predictive model will be valid. In particular, this
includes ensuring adequate iron supply and ener-
getic treatment of intercurrent complications, such
as infections and bleeding.
Therefore, while the various predictive algorithms
are promising, they require further refinement as
well as confirmation and comparison in a larger
number of patients. It is hoped that such algo-
rithms may help to ensure a more targeted
approach to the use of rHuEPO in the setting of the
chronic anemia of cancer. By administering rHuE-
PO and related products specifically to those
patients who have a high likelihood of responding
to treatment, the cost effectiveness of these med-
ications can be optimized to the advantage of both
patients and healthcare providers.
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Figure 4. Prediction of response to rHuEPO in anemia of
cancer patients using the baseline serum EPO level and the
2-week sTfR increment.39 (A) Baseline EPO >100 mU/mL,
n = 17; (B) Baseline EPO <100 mU/mL and sTfR increment
<25%, n = 7; (C) Baseline EPO <100 mU/mL and sTfR incre-
ment ≥25%, n = 24.
Iron supplementation
Owing to the increased erythropoietic activity
stimulated by rHuEPO, adequate delivery of iron to
the bone marrow is an important consideration in
all clinical situations in which rHuEPO is used,
including cancer (the relationship between rHuE-
PO, iron and erythropoiesis has been reviewed by
Goodnough et al.52). Functional iron deficiency is a
very frequent limitation of rHuEPO therapy. How-
ever, because there is some concern that tumor
cells require iron for optimal growth,53 routine iron
supplementation for all cancer patients receiving
rHuEPO is not recommended. The same is true for
both oral and intravenous iron supplementation.
However, this should be balanced with the fact that
transfusion of one RBC unit also provides a large
amount (200 mg) of iron.
Iron supplements should be given when absolute
iron deficiency is suspected, i.e. when serum ferritin
is 40-100 µg/L, a level associated with absence of
iron stores in ACD.4,24 Otherwise, iron supplements
should be given in the case of functional iron defi-
ciency, i.e. when the transferrin saturation is below
20% or the percentage of hypochromic RBCs is
greater than 10%, and may be discontinued when
they stabilize within the normal range. The expe-
rience in iron-replete renal failure patients has
clearly indicated that oral iron supplementation is
only marginally superior to no iron but that intra-
venous iron both substantially improves response
when rHuEPO therapy is initiated54 and allows con-
siderable reduction (in the order of 40%) of rHuE-
PO dose requirements during the maintenance
phase.55 The safety profile of iron saccharate, an
iron complex taken up by reticuloendothelial cells,
makes it the preferred intravenous compound over
iron dextran (more anaphylactic reactions) or iron
gluconate (more toxicity owing to free iron
release).56,57 According to the manufacturers’ rec-
ommendations, the maximum doses are 1000 mg
for iron dextran, 500 mg for iron saccharate and
62.5 mg for iron gluconate.58
Iron usage has not been energetically pursued in
clinical trials of rHuEPO in cancer patients and was
generally left to the discretion of the individual
investigator. This was based on the false percep-
tion that cancer patients do not have decreased
iron stores (ferritin) and thus, do not require iron
supplementation with rHuEPO therapy. In addition,
iron has only been given orally, a method proven to
be of little efficacy in renal failure patients and pre-
sumably even less effective in cancer patients
because of impaired iron absorption, another char-
acteristic of ACD.4,24 The efficacy of intravenous iron
to correct functional iron deficiency and improve
anemia has been well documented in rheumatoid
arthritis during rHuEPO therapy59 and after failure
of oral iron in juvenile chronic arthritis,60 two dis-
eases also associated with ACD. Apart from anec-
dotal reports on the efficacy of intravenous iron in
patients failing to respond to rHuEPO, iron supple-
mentation has not been formally studied in the
anemia of cancer. Probably, intravenous adminis-
tration of 100–300 mg iron saccharate every week
or every other week will ensure the best utilization
of any given dose of rHuEPO. Future clinical trials
are required to investigate the safety and efficacy
of intravenous iron in cancer patients treated with
rHuEPO.
Administration and dose–response
relationship of rHuEPO 
Several studies have suggested that raising the
dose of erythropoietic agents may increase
response rates if an inadequate response is seen
shortly after commencement of therapy,22,28,35 indi-
cating that an understanding of the dose–response
relationship of these agents is desirable. In a large,
open-label trial involving 2,370 patients with non-
myeloid malignancies, Demetri et al.22 reported that
patients whose Hb levels did not increase by ≥1
g/dL after 4 weeks of rHuEPO therapy received a
doubled dose of rHuEPO (from 10,000 to 20,000 U
three times weekly), and of these, 44% went on to
achieve either a Hb increase of ≥ 2 g/dL or a Hb lev-
el of ≥12 g/dL by the end of the study. Similarly, in
the study by Osterborg et al., patients had their
rHuEPO dose titrated from 2,000 U/day to 5,000
U/day if Hb had not reached 11 g/dL after 8 weeks
of therapy after eliminating the need for transfu-
sions, and then to 10,000 U/day if Hb had not
reached 11 g/dL by 12 weeks after eliminating the
need for transfusions.35 Fourteen percent of
patients receiving 2,000 U/day responded to rHuE-
PO therapy, and after stepwise escalation to 5,000
U and 10,000 U daily, the cumulative response rate
increased to 42% and 60%, respectively.
Reflecting the potential value of dose increases,
the approved dosing schedule for rHuEPO (three
times weekly by subcutaneous injection) includes
a dose-escalation for inadequate response. Using
the approved three-times-weekly dosing frequen-
cy, patients who are suitable for rHuEPO therapy
receive a starting rHuEPO dose of 150 U/kg. If an
inadequate hematopoietic response is observed
after 1 month of therapy (Hb increase <1 g/dL), the
dose can be doubled to 300 U/kg three times week-
ly. Since it is unlikely that patients who do not
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respond to 300 U/kg will respond to higher doses
of rHuEPO, therapy can be discontinued in non-
responding patients after 8 weeks of therapy. If Hb
levels rise to >13 g/dL, therapy should be discon-
tinued, but resumed at 75% of the previous dose
until Hb has dropped to ≤ 12 g/dL.
While the currently approved dosing schedule is
three times weekly, recent data from an open-label,
multicenter trial involving 3,012 anemic patients
with non-myeloid malignancies who were receiv-
ing chemotherapy suggest that once-weekly dos-
ing of rHuEPO is also feasible,28 and in fact a once-
weekly dosing schedule is common practice in the
United States. The trial by Gabrilove et al.28 indi-
cated that dose increases on a once-weekly sched-
ule were well tolerated and were associated with
an increase in response rates; however, longer
intervals between dosing may have a negative
impact on patient compliance as infrequent injec-
tions are difficult to remember. Patients initially
received 40,000 U rHuEPO once weekly by subcu-
taneous injection, and those whose Hb increased by
< 1 g/dL after 4 weeks of therapy had their rHuE-
PO dose increased to 60,000 U/week. The hema-
topoietic response rate to 40,000 U rHuEPO once
weekly was 49%, and this rose to 68% when
patients who required dose escalation had their
rHuEPO dose increased (33% of patients during the
16-week study). In this trial, hematopoietic
response was defined as an increase in Hb of ≥ 2
g/dL or achievement of a Hb level of ≥12 g/dL, with
no transfusions in the previous 30 days. The feasi-
bility of once-weekly subcutaneous dosing in
patients with lymphoproliferative malignancies has
also been demonstrated.61 Patients received either
rHuEPO 30,000 U/week or rHuEPO 10,000 U three
times weekly, with a dose increase to 60,000 U
weekly if Hb increased by <0.5 g/dL by week 5
and/or patients required a RBC transfusion during
week 4. Response to rHuEPO (Hb increase ≥ 2 g/dL
from baseline and no transfusions in the 6 weeks
before the last available Hb value) was similar in
both groups, at 72% and 75% for the once-weekly
and three-times-weekly schedules, respectively.
Despite the many trials in which patients
received a dose escalation, the precise dose-
response relationship for rHuEPO has not been
extensively evaluated, which may be inhibiting fur-
ther dose optimization. It is likely, however, that
there is a certain point beyond which the erythroid
marrow will be unresponsive to further increases in
rHuEPO dose.
Darbepoetin α
Further improvement on the EPO molecule may
arise from the development of darbepoetin α
(ARANESP™, Amgen Inc., Thousand Oaks, CA, USA),
a unique erythropoiesis stimulating protein. Dar-
bepoetin α is an erythropoietic protein that is sim-
ilar to EPO but has a higher sialic acid content than
endogenous EPO and rHuEPO, and a longer half-life
and greater biological activity than rHuEPO. In
addition to exploring the safety and efficacy of this
agent when given at less-frequent dosing intervals
than rHuEPO, clinical trials are underway to fully
characterize the dose–response relationship.
A large phase I/II clinical trial, involving anemic
patients with solid tumors receiving concurrent
chemotherapy, exploring the dose–response rela-
tionship of darbepoetin α, has indicated that the
higher the dose, the faster the response and the
greater the proportion of responders.62,63 In Part A
of this study, 60 patients were randomized to
receive rHuEPO (150–300 U/kg) and 228 to receive
darbepoetin α (1.5, 2.25, 4.5 µg/kg/week, among
other doses). Hematopoietic response rates (Hb ≥12
g/dL or ≥2 g/dL increase in Hb from baseline) ranged
from 53% (95% CI: 37,71) to 84% (95% CI: 70,98)
for darbepoetin α doses from 1.5 to 4.5 µg/kg/week.
In Part B of this study, in which 35 patients were
randomized to rHuEPO (40,000 U/week, increased
to 60,000 U/week if response was inadequate) and
141 patients to darbepoetin α (3.0, 5.0 and 9.0
µg/kg every 2 weeks), hematopoietic response
ranged from 66% (95% CI: 46,86) to 84% (95% CI:
67,100).62 Hematopoietic response rates for the 3.0
µg/kg and 5.0 µg/kg cohorts were 66% and 84%,
respectively, compared with 63% for rHuEPO.63
Generally, not only did higher doses of darbepoet-
in α result in higher hematopoietic response rates,
but they were also associated with faster times to
response, greater change from baseline Hb, and
greater decreases in RBC transfusions during treat-
ment. Overall, darbepoetin α was demonstrated to
be effective at doses above 1.5 µg/kg/week and 3.0
µg/kg every 2 weeks, and no loss of dose efficien-
cy was noted when the dosing interval was extend-
ed from once weekly to once every 2 weeks.64 There
also appeared to be a dose–response relationship in
the proportion of patients achieving a Hb response
and correction (Hb increase to ≥12 g/dL), and the
mean change in Hb from baseline in a placebo-con-
trolled study of 66 patients with lymphoprolifera-
tive malignancies who were receiving multicycle
chemotherapy.65 Furthermore, when the results of
two trials were compared, it was noted that the
dose–response of darbepoetin α appeared to be
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similar in patients with lymphoproliferative and sol-
id tumors.66
A phase III, placebo-controlled trial that evalu-
ated data from 314 patients indicated that once-
weekly darbepoetin αwas well tolerated and effec-
tive in reducing transfusion requirements and rais-
ing Hb.67 The activity of darbepoetin α has also
been demonstrated in patients who were not
receiving chemotherapy, with hematopoietic
response rates (Hb ≥12 g/dL or ≥2 g/dL increase in
Hb from baseline) of 100% observed at the high-
est once-weekly dose.68 Results from a phase II
clinical trial indicate that darbepoetin α can
improve hematopoietic response rates when given
as infrequently as once every 3 weeks, and a
dose–response relationship was observed at this
dosing interval.69
The dose–response relationship for darbepoetin α
when administered in three different loading
phase/maintenance phase schedules has also been
explored, and results suggest that early, higher dos-
es of darbepoetin α (lasting either 4 weeks or until
Hb has increased to ≥12 g/dL), followed by lower
and/or less frequent doses may provide an optimal
erythropoietic response.70 In this study, rHuEPO
(40,000 U/week, with a dose increase to 60,000
U/week if response was inadequate by week 8) was
the active control. After 4 weeks of therapy the
mean change in Hb was approximately 80%
greater in the three darbepoetin α groups than in
the rHuEPO group. Despite the reduction in dose in
the darbepoetin α groups in the latter part of the
study, the mean change in Hb from baseline to the
end of the study was still approximately 30%
greater following treatment with darbepoetin α
than with rHuEPO.
Extended dosing intervals, such as those being
explored in the darbepoetin α clinical trials, mean
that particular attention should be paid to patients’
compliance and to the difficulty in implementing
dose reductions in a timely fashion if needed. The
results from these studies indicate that, with dar-
bepoetin α at least, the majority of patients may be
able to respond to therapy, suggesting that titra-
tion rather than removal of therapy may be appro-
priate.
Conclusions
Extensive studies have demonstrated the clinical
efficacy of rHuEPO in improving Hb levels, trans-
fusion rates and QOL in patients with chronic can-
cer-associated anemia. While further research is
needed to refine our understanding of factors that
are predictive of response to rHuEPO, a number of
tools are currently available. Assessment of base-
line serum endogenous EPO levels should be
obtained before a chemotherapy cycle in patients
with lymphoma or myeloma (but not in solid
tumors), so that only patients with a relatively
impaired EPO response to anemia are given rHuE-
PO. Two weeks after starting rHuEPO therapy, mea-
surement of early indicators of erythropoietic mar-
row response (such as change in Hb >0.3–0.5 g/dL
or in sTfR >20–25% over baseline) can be recom-
mended. As an inadequate iron supply is likely to
limit the erythropoietic response to rHuEPO,
patients should be assessed at baseline as well as
during therapy for the presence of absolute or rel-
ative iron deficiency. Serum ferritin values below
40–100 µg/L identify absence of iron stores, while
measurement of transferrin saturation (< 20%) or
fraction of hypochromic RBCs (> 10%) is the best
way to diagnose functional iron deficiency. If a
patient is severely iron deficient, it may be prudent
to delay rHuEPO therapy until iron stores are
replenished, or to treat the iron deficiency aggres-
sively early in the course of rHuEPO therapy.
Although a number of factors may limit the effi-
cacy of rHuEPO therapy, the application of reliable
methods of predicting treatment response, the use
of iron supplements and the development of new
molecules promise significant improvements for
patients suffering from chronic anemia comorbid
with cancer. Prospective studies are warranted to
confirm the value of treatment algorithms using
rHuEPO or newer agents such as darbepoetin α.
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